240 related articles for article (PubMed ID: 30551530)
1. Molecular targeting for treatment of human T-lymphotropic virus type 1 infection.
Soltani A; Hashemy SI; Zahedi Avval F; Soleimani A; Rafatpanah H; Rezaee SA; Griffith R; Mashkani B
Biomed Pharmacother; 2019 Jan; 109():770-778. PubMed ID: 30551530
[TBL] [Abstract][Full Text] [Related]
2. HTLV-1-host interactions on the development of adult T cell leukemia/lymphoma: virus and host gene expressions.
Tarokhian H; Rahimi H; Mosavat A; Shirdel A; Rafatpanah H; Akbarin MM; Bari A; Ramezani S; Rezaee SA
BMC Cancer; 2018 Dec; 18(1):1287. PubMed ID: 30577817
[TBL] [Abstract][Full Text] [Related]
3. Human T-lymphotropic virus 1 (HTLV-1)-associated lichenoid dermatitis induced by CD8+ T cells in HTLV-1 carrier, HTLV-1-associated myelopathy/tropical spastic paraparesis and adult T-cell leukemia/lymphoma.
Tokura Y; Ito T; Kawakami C; Sugita K; Kasuya A; Tatsuno K; Sawada Y; Nakamura M; Shimauchi T
J Dermatol; 2015 Oct; 42(10):967-74. PubMed ID: 26077665
[TBL] [Abstract][Full Text] [Related]
4. Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects.
Gessain A; Mahieux R
Rev Neurol (Paris); 2012 Mar; 168(3):257-69. PubMed ID: 22405461
[TBL] [Abstract][Full Text] [Related]
5. Pathogenicity and virulence of human T lymphotropic virus type-1 (HTLV-1) in oncogenesis: adult T-cell leukemia/lymphoma (ATLL).
Ahmadi Ghezeldasht S; Blackbourn DJ; Mosavat A; Rezaee SA
Crit Rev Clin Lab Sci; 2023 May; 60(3):189-211. PubMed ID: 36593730
[TBL] [Abstract][Full Text] [Related]
6. [Virological aspects of HTLV-1 infection and new therapeutical concepts].
Mahieux R
Bull Soc Pathol Exot; 2011 Aug; 104(3):181-7. PubMed ID: 21607661
[TBL] [Abstract][Full Text] [Related]
7. The human T-cell leukemia virus type 1 (HTLV-1): new insights into the clinical aspects and molecular pathogenesis of adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM).
Shuh M; Beilke M
Microsc Res Tech; 2005 Nov; 68(3-4):176-96. PubMed ID: 16276549
[TBL] [Abstract][Full Text] [Related]
8. Silencers of HTLV-1 and HTLV-2: the pX-encoded latency-maintenance factors.
Harrod R
Retrovirology; 2019 Sep; 16(1):25. PubMed ID: 31492165
[TBL] [Abstract][Full Text] [Related]
9. Human T-lymphotropic virus 1 (HTLV-1) infection--dermatological implications.
Amano M; Setoyama M; Grant A; Kerdel FA
Int J Dermatol; 2011 Aug; 50(8):915-20. PubMed ID: 21781059
[TBL] [Abstract][Full Text] [Related]
10. Cytoplasmic Localization of HTLV-1 HBZ Protein: A Biomarker of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).
Baratella M; Forlani G; Raval GU; Tedeschi A; Gout O; Gessain A; Tosi G; Accolla RS
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005285. PubMed ID: 28095504
[TBL] [Abstract][Full Text] [Related]
11. HTLV-1 and associated adult T-cell leukemia/lymphoma.
Mahieux R; Gessain A
Rev Clin Exp Hematol; 2003 Dec; 7(4):336-61. PubMed ID: 15129647
[TBL] [Abstract][Full Text] [Related]
12. The effect of HTLV-1 virulence factors (HBZ, Tax, proviral load), HLA class I and plasma neopterin on manifestation of HTLV-1 associated myelopathy tropical spastic paraparesis.
Tarokhian H; Taghadosi M; Rafatpanah H; Rajaei T; Azarpazhooh MR; Valizadeh N; Rezaee SAR
Virus Res; 2017 Jan; 228():1-6. PubMed ID: 27845163
[TBL] [Abstract][Full Text] [Related]
13. High IFN-γ/IL-10 expression ratio and increased frequency of persistent human T-cell lymphotropic virus type 1-infected clones are associated with human T-cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis development.
Espíndola OM; Oliveira LC; Ferreira PM; Leite AC; Lima MA; Andrada-Serpa MJ
Intervirology; 2015; 58(2):106-14. PubMed ID: 25833232
[TBL] [Abstract][Full Text] [Related]
14. Modes of Human T Cell Leukemia Virus Type 1 Transmission, Replication and Persistence.
Carpentier A; Barez PY; Hamaidia M; Gazon H; de Brogniez A; Perike S; Gillet N; Willems L
Viruses; 2015 Jul; 7(7):3603-24. PubMed ID: 26198240
[TBL] [Abstract][Full Text] [Related]
15. Co-presentation of human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis and adult-onset infective dermatitis associated with HTLV-1 infection.
Okajima R; Casseb J; Sanches JA
Int J Dermatol; 2013 Jan; 52(1):63-8. PubMed ID: 23278610
[TBL] [Abstract][Full Text] [Related]
16. Human T cell lymphotropic virus type I (HTLV-I) p12I is dispensable for HTLV-I transmission and maintenance of infection in vivo.
Furukawa Y; Usuku K; Izumo S; Osame M
AIDS Res Hum Retroviruses; 2004 Oct; 20(10):1092-9. PubMed ID: 15585100
[TBL] [Abstract][Full Text] [Related]
17. Integration of gene co-expression analysis and multi-class SVM specifies the functional players involved in determining the fate of HTLV-1 infection toward the development of cancer (ATLL) or neurological disorder (HAM/TSP).
Zarei Ghobadi M; Emamzadeh R
PLoS One; 2022; 17(1):e0262739. PubMed ID: 35041720
[TBL] [Abstract][Full Text] [Related]
18. Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders.
Kozako T; Yoshimitsu M; Akimoto M; White Y; Matsushita K; Soeda S; Shimeno H; Kubota R; Izumo S; Arima N
Hum Immunol; 2011 Nov; 72(11):1001-6. PubMed ID: 21851845
[TBL] [Abstract][Full Text] [Related]
19. Drug targets in human T-lymphotropic virus type 1 (HTLV-1) infection.
Boross P; Bagossi P; Weber IT; Tözsér J
Infect Disord Drug Targets; 2009 Apr; 9(2):159-71. PubMed ID: 19275704
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of HTLV-1 infection and pathogenesis.
Yasunaga J; Matsuoka M
Int J Hematol; 2011 Nov; 94(5):435-42. PubMed ID: 21953273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
